

C1  
Claim 2. (Amended) An isolated tumor antigen peptide comprising an amino acid sequence that is a partial cyclophilin B sequence of SEQ ID NO:44, and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

C2  
Claim 4. (Amended) An isolated tumor antigen peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-36 and SEQ ID NOS: 41-43, wherein the peptide binds to HLA antigen and is recognized by cytotoxic T lymphocytes.

C3  
Claim 6. (Amended) A derivative of the isolated tumor antigen peptide of claim 4, in which the amino acid residue at position 2 and/or the C-terminus in the amino acid sequence is substituted by another amino acid residue, and in which the derivative binds to HLA antigen and is recognized by cytotoxic T lymphocytes.

C4  
Claim 8. (Amended) The derivative of claim 6, in which the amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOS: 1-11 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the amino acid residue at the C-terminus is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine.

Claim 9. (Amended) The derivative of claim 6, in which the amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOs: 12-36 is substituted by leucine, methionine, valine, isoleucine, or glutamine, and/or the amino acid residue at the C-terminus is substituted by valine or leucine.

C4 Claim 10. (Amended) The derivative of claim 8 comprising the amino acid sequence shown in SEQ ID NO: 37 or 38.

Claim 11. (Amended) The derivative of claim 10 comprising the amino acid sequence shown in SEQ ID NO: 39 or 40.

Claim 12. (Twice Amended) A composition comprising as an active ingredient at least one of substances selected from tumor antigen peptides and derivatives thereof according to any one of claims 2, 4, 6, 8, 9, 10 or 11.

---

C5 Claim 14. (Amended) A method for treating or preventing tumors, which comprises administering a patient in need cyclophilin B, a partial polypeptide of cyclophilin B that comprises a tumor antigen peptide portion which binds to an HLA antigen and is recognized by cytotoxic T lymphocytes, or a gene encoding cyclophilin B or a partial polypeptide thereof.

C5 Claim 15. (Twice Amended) An antibody that specifically binds to the tumor antigen peptide or the derivative thereof according to any one of claims 2, 4, or 6.

Claim 16. (Amended) An antigen-presenting cell wherein a complex between an HLA antigen and the tumor antigen peptide or the derivative thereof according to any one of claims 2, 4, or 6 is presented on the surface of a cell having antigen-presenting ability that is isolated from a tumor patient.

---

C6 Claim 20. (Twice Amended) A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and a tumor antigen peptide or derivative thereof according to any one of claims 2, 4, or 6.

---

C7 Claim 25. (Twice Amended) The composition of claim 12 wherein the composition is to diagnose tumors.

---

Attached hereto is a marked-up version of the changes made to the application by this Reply.